BLAINJECTIONSOLUTIONPriority Review
Approved
Oct 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INMAZEB is a combination monoclonal antibody therapy consisting of atoltivimab, maftivimab, and odesivimab-ebgn administered by intravenous injection. It is indicated for the treatment of Ebola virus disease (EVD) in adult and pediatric patients. The three-antibody cocktail targets different epitopes of the Ebola virus glycoprotein to neutralize the virus and reduce viral load.
Peak
Peak lifecycle stage indicates stable revenue and active brand team expansion; significant opportunity in medical affairs and clinical operations roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers
Started Jan 2027
132 enrolled
Ebola Virus Disease
Career Relevance
Working on INMAZEB positions you at the intersection of rare disease therapeutics, biodefense, and emergency preparedness—areas of strategic importance to Regeneron and government health agencies. The 357 linked jobs indicate a growing but specialized talent footprint focused on manufacturing scale-up, regulatory compliance, and medical education in outbreak response.
Medical Director
Worked on INMAZEB at Regeneron? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.